Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Rituximab infusion two months after nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD. 48th Annual Meeting of the American-Society-of-Hematology Arai, S., Sahaf, B., Jones, C., Zehnder, J., Lowsky, R., Strober, S., Shizuru, J., Negrin, R., Johnston, L., Laport, G., Goldstein, K., Brown, J. (., Miklos, D. AMER SOC HEMATOLOGY. 2006: 823A–823A
View details for Web of Science ID 000242440003696